Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : InvestRight - Short Term Trading St -- Ignore unavailable to you. Want to Upgrade?

To: Ray Tarke who wrote (869)	2/12/1999 11:40:00 AM
From: Jeffrey L. Henken	Respond to of 939

American BioMed, Inc., Receives Opening Order from Brazilian Distributor biz.yahoo.com THE WOODLANDS, Texas, Feb. 12 /PRNewswire/ -- American BioMed, Inc. (OTC Bulletin Board: ABMI - news), today announced that it has received opening orders from Syncrofilm Distribuidora Ltda of Sao Paulo, Brazil. According to Manuel Simplicio Neto, Syncrofilm Managing Director, ''We will over the next few months undertake the task of registering the American BioMed products so that full scale promotion can begin as soon as possible.'' According to Marshall Kerr, American BioMed Vice President of Sales and Marketing, ''We are very excited about this new addition to our distributor network. Brazil is one of the most active vascular surgery areas in the world. Training for the sales staff at Syncrofilm will begin early second quarter. With regulatory approval being accomplished in the second quarter significant revenue should be realized by year-end. In addition, we have continuing dialog with distributor prospects throughout Latin and South America.'' Commenting further, ''As is the case with Syncrofilm, American BioMed will concentrate on adding those distributors that can not only market our products but can also assist us in the regulatory process. Local knowledge of these procedures is key to achieving the approval to market in many countries around the world. American BioMed is continuing the search for quality distributors to add to our growing distribution network. This network will market our current product offerings and will serve as the launching platform for our new products planned for introduction later this year.'' American BioMed, Inc. utilizes state-of-the-art technology to develop, manufacture and market minimally invasive medical devices for the treatment of cardiovascular disease. The Company's products include 100%-silicone catheters, through its Cathlab subsidiary; the Evert-O-Cath(TM), a toposcopic catheter for site-specific drug delivery and fluid removal, the OmniCath®, an atherectomy catheter designed to remove atherosclerotic plaque from obstructed blood vessels throughout the body; and the OmniFilter, which is used to prevent blood clots from reaching various organs of the body. The Company has over twenty-five patents and 11 FDA approvals covering its product portfolio, and addresses an annual worldwide market estimated to be in excess of $10 billion. ''Safe Harbor'' statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in the release are forward-looking statements that involve risks and uncertainties including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive product development, commercialization and technological difficulties, the results of financing efforts, the effect of the Company's accounting policies, and other risks detailed in the Company's securities and Exchange Commission filings. For Further Information: American BioMed, Inc. 10077 Grogan's Mill Rd., #100 The Woodlands, TX 77380 281-367-3895 Contact: Steven B. Rash President & CEO